These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 37258721)

  • 1. A novel 5-gene prognostic signature to improve risk stratification of cytogenetically normal acute myeloid leukemia.
    Deng C; Zeng T; Zhu P; Zhao S; Huang Z; Huang W; Zhang W; Huang X; Fu L
    J Cancer Res Clin Oncol; 2023 Sep; 149(12):10015-10025. PubMed ID: 37258721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Higher Expression of
    Chen C; Chen Z; Chio CL; Zhao Y; Li Y; Liu Z; Jin Z; Wu X; Wei W; Zhao Q; Li Y
    Technol Cancer Res Treat; 2021; 20():15330338211052152. PubMed ID: 34738847
    [No Abstract]   [Full Text] [Related]  

  • 3. Association of a cytarabine chemosensitivity related gene expression signature with survival in cytogenetically normal acute myeloid leukemia.
    Yan H; Wen L; Tan D; Xie P; Pang FM; Zhou HH; Zhang W; Liu ZQ; Tang J; Li X; Chen XP
    Oncotarget; 2017 Jan; 8(1):1529-1540. PubMed ID: 27903973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prognostic value of RASGEF1A RNA expression and DNA methylation in cytogenetically normal acute myeloid leukemia.
    He X; Zhang W; Fu W; Liu X; Yang P; Wang J; Zhu M; Li S; Zhang W; Zhang X; Dong G; Yan C; Zhao Y; Zeng Z; Jing H
    Cancer Biomark; 2023; 36(2):103-116. PubMed ID: 36404533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical significance of FLT3-ITD/CEBPA mutations and minimal residual disease in cytogenetically normal acute myeloid leukemia after hematopoietic stem cell transplantation.
    Wang H; Li XQ; Chu TT; Han SY; Qi JQ; Tang YQ; Qiu HY; Fu CC; Tang XW; Ruan CG; Wu DP; Han Y
    J Cancer Res Clin Oncol; 2021 Sep; 147(9):2659-2670. PubMed ID: 33550446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A 6-Membrane Protein Gene score for prognostic prediction of cytogenetically normal acute myeloid leukemia in multiple cohorts.
    Lin SY; Miao YR; Hu FF; Hu H; Zhang Q; Li Q; Chen Z; Guo AY
    J Cancer; 2020; 11(1):251-259. PubMed ID: 31892991
    [No Abstract]   [Full Text] [Related]  

  • 7. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.
    Paschka P; Schlenk RF; Gaidzik VI; Habdank M; Krönke J; Bullinger L; Späth D; Kayser S; Zucknick M; Götze K; Horst HA; Germing U; Döhner H; Döhner K
    J Clin Oncol; 2010 Aug; 28(22):3636-43. PubMed ID: 20567020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Novel 85-Gene Expression Signature Predicts Unfavorable Prognosis in Acute Myeloid Leukemia.
    Lai Y; Sheng L; Wang J; Zhou M; OuYang G
    Technol Cancer Res Treat; 2021; 20():15330338211004933. PubMed ID: 33784904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined molecular and clinical prognostic index for relapse and survival in cytogenetically normal acute myeloid leukemia.
    Pastore F; Dufour A; Benthaus T; Metzeler KH; Maharry KS; Schneider S; Ksienzyk B; Mellert G; Zellmeier E; Kakadia PM; Unterhalt M; Feuring-Buske M; Buske C; Braess J; Sauerland MC; Heinecke A; Krug U; Berdel WE; Buechner T; Woermann B; Hiddemann W; Bohlander SK; Marcucci G; Spiekermann K; Bloomfield CD; Hoster E
    J Clin Oncol; 2014 May; 32(15):1586-94. PubMed ID: 24711548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Comprehensive Metabolism-Related Gene Signature Predicts the Survival of Patients with Acute Myeloid Leukemia.
    Zhai Y; Shen H; Wei H
    Genes (Basel); 2023 Dec; 15(1):. PubMed ID: 38254953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia.
    Metzeler KH; Hummel M; Bloomfield CD; Spiekermann K; Braess J; Sauerland MC; Heinecke A; Radmacher M; Marcucci G; Whitman SP; Maharry K; Paschka P; Larson RA; Berdel WE; Büchner T; Wörmann B; Mansmann U; Hiddemann W; Bohlander SK; Buske C; ;
    Blood; 2008 Nov; 112(10):4193-201. PubMed ID: 18716133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ERG expression is an independent prognostic factor and allows refined risk stratification in cytogenetically normal acute myeloid leukemia: a comprehensive analysis of ERG, MN1, and BAALC transcript levels using oligonucleotide microarrays.
    Metzeler KH; Dufour A; Benthaus T; Hummel M; Sauerland MC; Heinecke A; Berdel WE; Büchner T; Wörmann B; Mansmann U; Braess J; Spiekermann K; Hiddemann W; Buske C; Bohlander SK
    J Clin Oncol; 2009 Oct; 27(30):5031-8. PubMed ID: 19752345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High NCALD expression predicts poor prognosis of cytogenetic normal acute myeloid leukemia.
    Song Y; Zhang W; He X; Liu X; Yang P; Wang J; Hu K; Liu W; Zhang X; Jing H; Yuan X
    J Transl Med; 2019 May; 17(1):166. PubMed ID: 31109331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of CD34, TdT, CD56, CD2, CD4, and CD14 by flow cytometry is associated with NPM1 and FLT3 mutation status in cytogenetically normal acute myeloid leukemia.
    Dalal BI; Mansoor S; Manna M; Pi S; Sauro GD; Hogge DE
    Clin Lymphoma Myeloma Leuk; 2012 Aug; 12(4):274-9. PubMed ID: 22481022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Favorable prognostic impact of NPM1 gene mutations in childhood acute myeloid leukemia, with emphasis on cytogenetically normal AML.
    Hollink IH; Zwaan CM; Zimmermann M; Arentsen-Peters TC; Pieters R; Cloos J; Kaspers GJ; de Graaf SS; Harbott J; Creutzig U; Reinhardt D; van den Heuvel-Eibrink MM; Thiede C
    Leukemia; 2009 Feb; 23(2):262-70. PubMed ID: 19020547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA Repair Expression Profiling to Identify High-Risk Cytogenetically Normal Acute Myeloid Leukemia and Define New Therapeutic Targets.
    Gabellier L; Bret C; Bossis G; Cartron G; Moreaux J
    Cancers (Basel); 2020 Oct; 12(10):. PubMed ID: 33036275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.
    Metzeler KH; Maharry K; Radmacher MD; Mrózek K; Margeson D; Becker H; Curfman J; Holland KB; Schwind S; Whitman SP; Wu YZ; Blum W; Powell BL; Carter TH; Wetzler M; Moore JO; Kolitz JE; Baer MR; Carroll AJ; Larson RA; Caligiuri MA; Marcucci G; Bloomfield CD
    J Clin Oncol; 2011 Apr; 29(10):1373-81. PubMed ID: 21343549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognosis and Characterization of Immune Microenvironment in Acute Myeloid Leukemia Through Identification of an Autophagy-Related Signature.
    Fu D; Zhang B; Wu S; Zhang Y; Xie J; Ning W; Jiang H
    Front Immunol; 2021; 12():695865. PubMed ID: 34135913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic implications of NPM1 mutations and FLT3 internal tandem duplications in Egyptian patients with cytogenetically normal acute myeloid leukemia.
    Shamaa S; Laimon N; Aladle DA; Azmy E; Elghannam DM; Salem DA; Taalab MM
    Hematology; 2014 Jan; 19(1):22-30. PubMed ID: 23540998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study.
    Becker H; Marcucci G; Maharry K; Radmacher MD; Mrózek K; Margeson D; Whitman SP; Wu YZ; Schwind S; Paschka P; Powell BL; Carter TH; Kolitz JE; Wetzler M; Carroll AJ; Baer MR; Caligiuri MA; Larson RA; Bloomfield CD
    J Clin Oncol; 2010 Feb; 28(4):596-604. PubMed ID: 20026798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.